Altimmune (ALT) vs Arvinas (ARVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arvinas (ARVN) has outperformed Altimmune (ALT) over the past year, losing 23.0% versus a loss of 34.8%. Over five years, ALT leads with a -78.3% price change compared with -91.2% for ARVN. Altimmune is the larger company by market cap ($507.7 million vs $492.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | ARVN |
|---|---|---|
| Share price | $2.61 | $7.64 |
| Market cap | $507.69M | $492.94M |
| 1-day change | +0.38% | +1.73% |
| YTD return | -27.70% | -36.68% |
| 1-year return | -34.75% | -22.97% |
| 5-year return | -78.27% | -91.18% |
| P/E ratio (TTM) | — | 29.38 |
| EPS (TTM) | $-0.76 | $0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $14.51 |
| 52-week low | $2.55 | $6.97 |
| Distance from 52-week high | -59.47% | -47.35% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +555.56% | +82.33% |
| Average volume | 4.23M | 788.21K |
| Shares outstanding | 194.52M | 64.52M |
| Employees | 57 | 246 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed ALT by 11.8 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
ALT vs ARVN FAQ
Which is bigger, Altimmune or Arvinas?
Altimmune (ALT) is larger, with a market capitalization of $507.69M compared with $492.94M for Arvinas (ARVN).
Which stock has performed better over the past year, ALT or ARVN?
ARVN returned -22.97% over the past 12 months, compared with -34.75% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Arvinas in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.